# Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

> **NCT02581163** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 314 (actual)

## Conditions studied

- Chronic Hepatitis C, Genotype 1 or 4

## Interventions

- **DRUG:** Ombitasvir/paritaprevir/ritonavir
- **DRUG:** Dasabuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02581163
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-07
- **Primary completion:** 2018-02-12
- **Final completion:** 2018-02-12
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2019-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581163, "Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT02581163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*